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ABSTRACT
Purpose: As preemptive pharmacogenetics expands in the academic healthcare setting, further
study is needed to assess the views of additional stakeholders in the marketplace on this
technology and the barriers and facilitators to their uptake. The purpose of this study is to
investigate the perspectives and opinions about coverage policies for preemptive
pharmacogenetic testing of third-party payers.
Methods: A qualitative study utilizing a blended inductive and directed approach was
conducted. A screener survey determined interview eligibility as well as demographic data.
Semi-structured interviews were conducted with payers from organizations of varying structure
and beneficiary populations. Meaning units and codes were used for each interview and
aggregated to identify the subthemes and major themes.
Results: A total of 14 payers were interviewed, covering 122,000,000 million lives, or almost
40% of the U.S. population. Positive and negative opinions were noted. Most positive opinions
were prefaced with a position that pharmacogenetics held great potential for the healthcare
system, but that full implementation was several years away. The work of the Clinical
Pharmacogenetics Implementation Consortium (CPIC) and the Pharmacogenomics Research
Network (PGRN) was viewed favorably. However, this would not drive policy decisions.
Negative opinions came from a concern of the lack of data that would make these tests
actionable for a payer from a policy development point of view. Concerns about the cost of
testing large numbers of people was mentioned frequently, as well as the inability to predict
ii

when a patient or physician would use the data from a test or potential cost savings from the
technology.
Discussion: Preemptive pharmacogenetic testing remains a cautious pursuit for many payers.
Lacking clinical outcomes data, the inability to evaluate the economic benefits from testing, and
high costs are a few central concerns. Real-world implementations from academic institutions
and the work of CPIC were seen as promising endeavors. The research community of
pharmacogenetic advocates should review this study and focus their efforts on providing the data
needed to guide informed policy decision making with regard to pharmacogenetic testing.
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1. INTRODUCTION
Clinical pharmacogenetics has the potential to be one of the next great innovations in
precision medicine and tailoring of patient treatments. The phrase, "the right drug, at the right
dose, the first time", has become synonymous with pharmacogenetic testing and the
improvements that it may possibly bring. This hope has been met with significant barriers to
implementation, due to claims by some of insufficient clinical evidence and results which have
not been integrated into the decision making process of clinicians.1
The most common form of pharmacogenetic testing is the point-of-care or "reactive"
testing method and it can occur in two forms: the testing of somatically acquired genomic
variation and the testing of germline genomic variation. A commonality between the forms is
that the patient is diagnosed with a condition and subsequently given the test or the companion
diagnostic to determine the appropriate course of treatment. The difference in the reactive form
comes from the type of reactive test, the genotyping of the patient or of a tumor. The former
corresponds to the germline genomic variation, and the latter to the somatically acquired
genomic variation. The genotyping of the patient will identify a specific gene variation that
impacts human drug metabolism, transport, distribution, and excretion for certain medications.
Genotyping of the tumor has been used to guide decisions on the type of anticancer agent
to use based on the likelihood of a response, and to develop novel therapies that target specific
genetic mutations within the tumor. Inherited genome variations in cancer can also influence
response. The desired outcome for genotyping the patient or the tumor is to characterize the
1

corresponding drug response phenotypes such as efficacy, toxicity, or desired pharmacologic
effects. This has become the more difficult challenge for pharmacogenetics as well translating
these discoveries into clinical practice. 2
The development of a newer form of testing for germline genomic variations, preemptive
pharmacogenetic testing, takes a broader approach to genotyping the patient by assaying
thousands of genetic variants with a single test with the results being entered into a patient's
electronic health record for future reference. Current adoption of preemptive pharmacogenetic
testing has been limited to a few consortiums composed mostly of academic medical centers.
These include the Pharmacogenetics Research Network (PGRN), the Electronic Medical Records
and Genomics Network (eMERGE), and Implementing GeNomics in Practice (IGNITE).The
costs of implementing the technology, to this point, has fallen predominantly on the individual
institution through the pursuit of grants and internal funding. Many of these programs are
supported by the National Institutes of Health (NIH) and the National Human Genome Research
Institue (NHGRI). This has limited the spread of this technology to only a few locations and
clinical settings.
These tests have struggled to gain widespread coverage among third-party payers,
although the testing of somatically acquired genomic variation has enjoyed slightly more success
in that regard.3 Historically, payers have identified the need for more data on clinical outcomes
and prospective comparative-effectiveness studies, ideally randomized-controlled trials, as well
as evidence that clinical utility exists to consider coverage for these types of tests.4,5 The clinical
utility of these tests has become a more important consideration for payers, as they pursue the
real-world applicability of medical innovations. 4,6
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The primary objective of this research is to investigate the perspectives and opinions
about coverage and reimbursement policies for preemptive pharmacogenetic testing from thirdparty payers through a series of in-depth interviews.

3

2. BACKGROUND
To many health care leaders, an emphasis on value has been the driving force behind
decision making in recent years. Value is a relationship between desired outcomes and the cost
needed to achieve those outcomes.7 Precision or personalized medicine is thought by many
health care leaders to be a way to increase value by leaving the population-based treatment
approach behind and advancing to a patient-centered model of care.7 The Personalized Medicine
Special Interest group of the International Society of Pharmacoeconomics and Outcomes
Research (ISPOR) defines personalized medicine as follows: the use of genetic or other
biomarker information to improve safety, effectiveness, and health outcomes of patients via more
efficiently targeted risk stratification, prevention, and tailored medication and treatmentmanagement approaches.8 The NIH has encouraged the adoption of the term "precision" over
"personalized" when discussing pharmacogenetics as to prevent the misinterpretation that a
treatment or prevention has been developed for an individual. 9 The term precision medicine is
the broadest of all terms and also seeks to include non-genomic factors such as lifestyle and
environment.

Overview of Pharmacogenetic Testing
It is important to note that the focus of pharmacogenetics must be distinguished from other areas
of clinical genomics that focus on the identification or risk of genetic or chromosomal
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conditions. Pharmacogenetics works by determining how germline or somatic mutations affect
the metabolic pathways that determine an individual's response to a drug.10 A germline mutation
is a detectable or heritable variation in the lineage of germ cells, while a somatic mutation is a
genetic alteration that is acquired by a cell and then passed along during cell division. Somatic
mutations, with respect to pharmacogenetics, are mostly involved in the detection of genetic
variants in the cells of tumors and related drug response. Pharmacogenetic testing does not focus
on the identification of disease risk, and there is little importance that can be gleamed from
assessing the genomic variants of an individual and this relationship. In so doing this test avoids
some of the ethical issues surrounding other types of genetic testing. 1
The discovery of the hepatic cytochrome P450 in 1977 was one of the most important
discoveries for the advancement of pharmacogenetics. 11 The CYP450 gene superfamily is
involved in the metabolism of about 75% of commonly prescribed drugs. The polymorphic drug
metabolism enzymes associated with CYP450 genes are prone to variations in the number of
copies, including full gene deletion or duplication, which ultimately effects how a drug would be
metabolized within a patient’s body affecting the safety and efficacy with some patients. The
genotypes of these enzymes are typically categorized as five metabolism phenotypes: ultrarapid,
rapid, normal, intermediate, and poor. 11 Take the CYP2D6 enzyme, a member of the CYP450
gene superfamily, for example, a patient that presents with multiple copies of this may be
classified as a rapid metabolizer of certain medications and will therefore require an increased
dose. Conversely, for a patient lacking functional CYP2D6 enzymes the normal dose would
exceed the therapeutic target, potentially resulting in an adverse drug reaction (ADR). ADRs are
a significant safety risk, causing increased morbidity and associated high costs, as well as being
one of the most common causes of death. 12 Many patient factors may contribute to an increased
5

risk of an ADR, but somewhere between 10-20% of ADRs are due to genetic factors.13 By
determining the mechanisms and effects of a genomic variation on drug response these kinds of
ADRs can be prevented.

Benefits of Pharmacogenetic Testing
Pharmacogenetic testing in clinical practice may benefit the patient in several ways. The
use of a pharmacogenetic test can enable more patient-centered care by involving the patient in
the decision making process.14 This involvement in the treatment decisions is likely to be
associated with a better patient-physician relationship and increased trust, leading to the potential
for greater adherence to the medication therapy. 15 They may perceive the therapy is more
beneficial or has less risks, given the pharmacogenetic test results have informed the treatment
choice. Also, patients who participate in pharmacogenetic testing may be psychologically
affected in a manner which encourages a more active role in their own health management.
Because the results of the pharmacogenetic tests inform the selection and dosing of drug therapy,
these tests are likely to address patient concerns about therapy. Some patients may perceive little
or no need for a therapy or doubt its effectiveness. If the pharmacogenetic test results indicate
that this therapy is likely to work in this patient, the patient may be more willing to adhere to the
medication therapy. 14
Similarly, using pharmacogenetic test results is a proactive medication safety strategy
that can provide information to decrease the risk of adverse drug reactions (ADRs) and improve
drug selection. Recall the example of the patient with multiple copies or a deletion of a CYP2D6
enzyme in the CYP450 gene, consequently requiring increased or decreased drug dosing,
6

respectively, to offset the change in metabolization. The identification of genetic factors that may
predispose a patient to an ADR can be helpful in preventing its occurrence. 16 Pharmacogenetic
testing will also help select effective therapy initially. A landmark psychiatric clinical trial
(STAR-D), completed in 2006 for patients with major depressive disorder, showed that only onethird of patients achieved remission from their initial treatment, meaning that patients generally
need to try multiple medications.17 The burden of switching to different therapies to find an
effective treatment can be costly for patients and the entire health care system as well as slow the
treatment of their condition.18 The problem is compounded depending on the number of
medication changes, which are required, and the time necessary to find the correct therapeutic
approach. Furthermore, early detection and treatment with an appropriate drug lessen the effects
of the disease on the body, arriving at better clinical outcomes for the patient. 14 The concomitant
research on the economic utility for many pharmacogenetic tests combined with clinical
evidence will be a determinant of potential value to the health system.
A study from 2014 identified 59 cost-utility analyses of precision medicine tests between
the years 1998 and 2011. The findings from the 2014 study revealed that most studies (72%)
showed testing provided better health at higher cost, while 20% showed cost saving. 19 Cost
saving in this case means that a negative incremental cost effectiveness ratio (ICER) resulted
from the analysis. Roughly half of the studies that provided better health at higher cost fell under
the $50,000/QALY threshold while 80% of the studies fell under the $100,000/QALY threshold.
The former $50,000/QALY threshold is used as a decision tool by the National Institute of
Health and Clinical Excellence in England (NICE) and the $100,000/QALY threshold is used
unofficially in the United States. 19,20 It is important to note however that there are many factors
which can influence the outcomes for the economic value of pharmcogenetic testing, including
7

test cost, treatment cost, the nature of the indication, treatment benefits with and without the test,
and the prevalence of the pharmacogenetic variant.20
In a recent study, Brixner et al. used an observational study design of elderly patients
(≥65 years old) with a prescription or dose change of at least one of sixty-one oral drugs within
120 days of enrollment that were on 3 or more total medications. 21 This prospective group was
propensity score matched with a retrospective cohort from a claims database. The prospective
group was given a CYP 450 pharmacogenetic test and providers used a clinical decision support
tool including this new information on patients for a four-month period to measure healthcare
resource utilization. Those patients in the tested group showed a significantly lower rate in
hospitalizations, 9.8% vs. 16.1%, p<0.027, and in emergency department visits, 4.4% vs. 15.4%,
p<0.0002. The rate of healthcare resources utilization was higher in the tested group, most likely
due to more outpatient visits, but the potential cost savings were estimated at $218 per patient in
the tested group.
The economics of health care and drug discovery can also benefit from the expansion of
pharmacogenetics in the industry. Deverka et al. explain that developing products through
pharmacogenetics can reduce the cost of drug development programs by allowing for smaller
and less expensive clinical trials, reducing the development time for a product, and increasing
FDA approval rates.18 Moreover, pharmacogenetics could be used to "rescue" certain drugs that
may have never made it to market because of severe ADRs. For example, the drug could be
made available to the cohort of patients who test negative for the genetic variant leading to the
ADR. However, because pharmaceutical companies will be catering to a much more stratified
population, incentives such as longer patent life and beneficial pricing contracts will be essential
to encourage this type of drug discovery.
8

Types of pharmacogenetic testing
There exist two broad groups of pharmacogenetic testing: somatic and germline testing,
the latter can be subdivided into reactive/point-of-care testing and preemptive testing. The
following section provides a brief discussion of each of these types.

Reactive-Somatic/companion diagnostic tests
As pharmacogenetic testing has progressed so has the availability of more advanced types
of testing. This has led to the development of what is commonly referred to as “companion
diagnostic tests”. These tests are typically developed and tested concurrently with the drug in the
early phases of clinical trials.5 The goal of these companion tests is to genotype the tumor and
break down the complexity, thereby identifying potential tailored treatments for specific types of
patients.4 It is suggested that the use of the companion diagnostics will facilitate selection of
appropriate treatment and lead to better medication-related outcomes. Additionally, it may
prevent money being spent on expensive, advanced biologic drug therapy for patients with
tumors not likely to respond to the drug therapy. Drug development in oncology products has
been an active area of research for pharmacogenetics, particularly in lung and breast cancer.
Currently, the United States Federal Drug Administration (FDA) requires pharmacogenetic
testing for use of trastuzumab, cetuximab, and panitumumab.
Some companion diagnostics may be co-developed with a drug and by the manufacturer
of that drug, while independent companies may develop tests for drugs that are currently used in
medical practice. Experts see the development of post hoc companion diagnostics growing
moderately over the coming years.5 The acceptance and use of germline mutation diagnostic
9

testing has been noticeably less than that of its somatic counterparts used in the treatment of
cancer. A major cause of this discrepancy may be the impact that testing in cancer products has
on the reduction in utilizing expensive medications in patients where the drug therapy is not
likely to work.

Reactive-Germline mutation testing
Germline mutation testing can be divided into two main groups: reactive or point-of-care
and preemptive pharmacogenetic testing. Reactive pharmacogenetic testing is the one-at-a-time
approach where the test is typically ordered at the point of care when initiating a treatment. 22
Support for the use of reactive pharmacogenetic testing comes from the assumption that there is
an increased likelihood the results will be applied by the clinician because the prescribing
decision will be inexorably linked to the results of the pharmacogenetic test. Furthermore, the
gene-by-gene basis of testing allows for the testing to be done on those patients who have been
diagnosed with a specified condition. 1 This can have both advantages and disadvantages. One
advantage is that unnecessary testing is avoided and the subsequent cost associated by offering
the pharmacogenetic test only to those with a specific indication.
A budget impact analysis of CYP2C19 genotyping in patients receiving dual antiplatelet
therapy including clopidogrel, which is known to incur serious ADRs for poor and intermediate
metabolizers, was recently conducted.23 The model assumed that patients had been diagnosed
with acute coronary syndrome (ACS) and would have received a percutaneous coronary
intervention (PCI). The budget impact was considered for three clinical scenarios: no patients
received CYP2C19 genotyping, 50% of patients received the genotyping, or all patients received
10

the genotyping. Demonstrating the feasibility of targeted genotyping, the results showed annual
cost-savings to the plan in both the 50% and 100% testing scenarios, $222,426 and $444,852,
respectively.
There exist several disadvantages to the reactive approach as well. Once the
determination has been made to test, it must be "ordered, retrieved, and interpreted by the
physician" before applying any changes to the patient's treatment. 22 A slow turnaround time can
lead to insufficient time being available before a clinical decision for drug therapy needs to be
made. Additionally, clinicians may lack the knowledge on gene/drug relations to enable them to
even initially order the appropriate tests when needed. 1 Testing on a per-gene basis can lead to an
increased cost if repeated tests are needed for complicated patients on multiple genetically
dependent therapies. The author of the budget impact analysis described previously only
considered the one genotype, he addresses the potential for further cost-savings from a
preemptive genotyping approach that enables decreased testing costs for individual genotypes
and integration with clinical decision support tools. 23

Preemptive-Germline mutation testing
The alternative pharmacogenetic testing approach is to preemptively test patients for
multiple pharmacogenetic variants. A large retrospective study on 52,942 medical home patients
conducted by Vanderbilt University Medical Center (VUMC) found that almost 65% of patients
were exposed to at least one medication with a drug label indicating a known pharmacogenetic
variation in response during the five year time period, and 54% were exposed within a one year
time frame. Using probabilities of medication exposure and probability of six possible severe
11

adverse events, the researchers estimated that 383 adverse events could have been prevented with
the implementation of an effective preemptive genotyping program. 22
The ability to assay hundreds to thousands of genetic variants at a time can decrease the
cost of individual genotyping, and provide genetic information that can be reused over the
lifetime of a patient as other drugs are prescribed. Multi-gene testing in a single assay benefits
the patient in another manner due to the fact that the pharmacokinetics and pharmacological
effects of a great majority of medications are determined by multiple gene products. The
adjustment of dosing based on a single-gene genetic test results, in some cases, can reveal
genetic variants in other genes that might be of clinical importance. Additionally, a single gene
can affect more than one medication (TPMT, CYP2D6, CYP2C19, CYP2C9, HLA-B, DPYD,
UGT1A1) and the preemptive availability of these results makes better use of this genetic data. 2
New drug-gene interactions are discovered continually, and the use of multiplexed preemptive
testing and successful clinical support tools will enable clinicians to apply immediately this new
knowledge to improve patient outcomes.
The St. Jude Children's Research Hospital protocol, PG4KDS, was opened in 2011 and as
of the end of 2013, the results of four genes have been implemented into the EHR. This
corresponds to 12 high-risk drugs and 55 clinical decision support systems. The data from this
protocol also showed that 78% of patients had at least one actionable genotype result. 24 Currently
there are seven genes coupled with 17 high-risk drugs that have been integrated into the EHR. 25
Another study conducted in the VUMC Predict program preemptively genotyped 10,000 patients
and found results, based on five drug-genome interactions, which identified one or more
actionable variants in 91% of overall patients and 96% of black patients. 26 The genetic data of
9,589 individuals was compared with historical published allele frequencies. The authors point
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out that it would have taken 14,656 total tests using a reactive genotyping approach, a nearly
50% increase in the amount of testing. Current thought is that most actionable drug prescribing is
linked to 12 genes. Dunnenberger et al. theorized that based on this, 98.5% of whites and 99.1%
of blacks, would present with at least one high-risk diplotype.1 The utility of pharmacogenetic
testing is contingent upon the prevalence of patients who receive high-risk pharmacogenetically
driven drugs and have phenotypes that predict a variable response. Thirty of the most common
prescription drugs considered pharmacogenetically high risk accounted for approximately 738
million prescriptions in 2013.

Implementing Preemptive Pharmacogenetic Testing in Practice
The Pharmacogenomic Research Network (PGRN) is at the forefront of preemptive
pharmacogenetics and its successful implementation into the health care system. PGRN is a
group of prominent researchers and clinicians at several academic hospitals throughout the U.S.
that are coordinating with the National Institute of General Medical Science (NIGMS) and the
National Institutes of Health (NIH) to study how genetic variation contributes to interindividual
differences in responses to medication. 27 Other than VUMC, there are several more highly
regarded academic research medical institutions that are undertaking similar preemptive testing
strategies. A few of these include St. Jude Children's Research Hospital, Mayo Clinic, Mount
Sinai Medical Center, University of Florida and Shands Hospital, the University of Chicago, and
Brigham and Women's Hospital.1
The VUMC PREDICT program was created in 2010 to target "high value genetic
variants" that contribute to medication-related adverse events through a preemptive genotyping
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of patients. The relationship between variants of CYP2C19 genotypes and antiplatelet therapy
was the initial focus. PREDICT uses the VeraCode ADME Core Panel to genotype their patients,
testing for 184 variants in 34 genes associated with drug response. 1,28 Four of the other
institutions listed previously have implemented similar multi-gene preemptive pharmacogenetic
testing platforms including Mount Sinai Medical Center (Sequenom iPLEX ADME
pharmacogenetic - 36 genes), Mayo Clinic (PGRNseq - 84 genes), St. Jude Children's Research
Hospital (Affymetrix DMET Plus Array - 230 genes), and University of Florida and Shands
Hospital (Life Technologies Quant Studio Open Array - 120 genes).1
The actionability of a drug/gene relationship is ultimately dependent upon the translation
of genome discoveries into systems that optimize the delivery of medications. An essential
aspect of this actionability is the availability of alternative therapies when a high-risk genotype
has been identified in a patient. This requires efforts by researchers to not only recognize the
drug/gene relationship that may be harmful, but to also identify an alternative therapy. 2 Work by
the Clinical Pharmacogenetics Implementation Consortium (CPIC), has taken a leadership role in
addressing this complex issue in pharmacogenetics. Many of these programs rely on the CPIC
guidelines to provide the clinical evidence of the drug/gene pair that is being tested and
potentially moved into the electronic health record (EHR). The importance of the EHR and
clinical informatics in the dissemination of preemptive pharmacogenetics has not been
overlooked. Many of the institutions mentioned above have developed clinical decision support
tools personalized to the high-risk medications likely to be prescribed based on the preemptive
testing results. St. Jude Children’s Research Hospital published a detailed report on the
development and use of their system. 29 Entries are created for high-risk phenotypes that deliver
post-test alerts when the high-risk drug is prescribed. The CDS system will also alert the
14

clinician when a high-risk medication is prescribed prior to genetic results being entered into the
patient’s EHR. The mission of CPIC is to inform clinicians on how genetic test results should be
used to improve patients’ outcomes, not when and whether to use them.30
The University of Chicago’s "1,200 Patients Project" aimed to determine the relevance of
pharmacogenetic results while delivering care in an outpatient clinic. As of 2014, 812 patients
had participated and 608 have been successfully genotyped. This protocol used the result signals
green light (favorable), yellow light (caution), and red light (high risk) via a genomic prescribing
system (GPS). At 268 clinic encounters, 86% of physicians accessed the GPS with 57% green
lights, 41% yellow lights, and 1.4% red lights. Also, physician click frequencies were reported as
20%, 72%, and 100%, respectively. This information shows a high rate of physician adoption
and widespread use in the patient population. 31
Approximately 15% of European Union-European Medicines Agency (EU-EMA) and the
US-FDA approved medications have some type of pharmacogenetic data in the label. 32,33
According to CPIC, only about 7% of these medications have actionable germline
pharmacogenetics. However, a disproportionate amount of these medications (18%) represent all
prescriptions in the United States. 2 Though only representing a small portion of the total
medications consumed in the U.S., the potential for improving current patient outcomes exist and
will be expanding as more actionable drug/gene relationships are identified. The design of CPIC
was realized through a collaboration of PGRN and NIGMS, described above, on the view that
preemptive genetic testing will become more widespread and clinicians will need the appropriate
evidence to make informed and accurate decisions quickly.
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The guidance that CPIC provides to clinicians is based on standardized guidelines to
understand the types and levels of evidence needed to justify the implementation of
pharmacogenetics into clinical practice. This evidence includes:
"…sound scientific rationale linking genomic variability with drug effects, the
therapeutic index of the involved medications, the severity of the underlying disease, the
availability of alternative dosages or drugs for patients with high-risk genotypes, the
availability of CLIA approved laboratory tests, and peer-reviewed clinical practice
guidelines that incorporate pharmacogenetics in their recommendations."34
Each guideline contains a summary of the drug dosing addressed from the genotype tests, a
literature review, genetic test interpretation for clinicians, population studies to compliment this
interpretation if available, genetic test options, possible incidental findings from the test, linkage
of genetic variability to variability in drug-related phenotypes, and levels of evidence and
strength of recommendations.
The prioritization of CPIC gene/drug pairs uses a subset of two rating schemes adapted
from National Academy of Clinical Biochemistry for the quality of the evidence and the National
Institutes of Health for the strength of the recommendation. 34 CPIC will apply this approach to
the development of each guideline.
The schema for evaluating the quality of evidence for a linkage between drug-related
phenotypes to specific genetic variations is as follows:
Level 1: the evidence includes consistent results from well-designed, well-conducted
studies
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Level 2: the evidence is sufficient to determine the effects, but the strength of the
evidence is limited by the number, quality, or consistency of the individual studies, by the
inability to generalize to routine practice, or by the indirect nature of the evidence.
Level 3: the evidence is insufficient to assess the effects on health outcomes because of
the limited number of studies, insufficient power of the studies, important flaws in their
design or in the way they were conducted, gaps in the chain of evidence, or lack of
information.
The schema for evaluating the strength of the recommendation to clinicians involved in decision
making is as follows:
A: strong recommendation for the statement
B: moderate recommendation for the statement
C: optional recommendation for the statement

CPIC is a joint project with PGRN and the Pharmacogenomics Knowledge Base
(PharmGKB), which is managed by Stanford University and trademarked by the U.S.
Department of Health and Human Services (HHS) that "encompasses clinical information
including dosing guidelines and drug labels, potentially clinically actionable gene-drug
associations and genotype-phenotype relationships."35 PharmGKB uses a similar rating system to
the one listed above but focuses rather on the genotype-based pharmacogenomic summaries of
the association between a drug and particular variant. These clinical annotations are assigned a
level (1A, 1B, 2A, 2B, 3, and 4), in descending order of strength of evidence for the association,
based on population, replication, effect size, and statistical significance.
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There are currently 36 variant-drug combinations that are listed level 1A. PharmGKB
defines level 1A as the "annotation for a variant-drug combination in a CPIC or medical societyendorsed pharmacogenetic guideline, or implemented at a PGRN site or in another major health
system."36 CPIC has designated its levels for gene-drug pairs as either: A, B, C, D. It is important
to note that these are not the same as the clinical annotations of PharmGKB, although there is
some overlap. There are currently 41 gene-drug pairs that have the designation CPIC Level A
and 97 designated CPIC Level B. Level A means that at least one moderate or strong action
(change in prescribing) is recommended, while level B indicates at least one optional action is
recommended. The PharmGKB annotation levels are incorporated in the prioritization process of
CPIC guidelines of new gene-drug pairs. There are currently 30 guidelines available. A flow
chart of this process is illustrated in Figure 1. 37 For a full list of the clinical annotation levels of
evidence from PharmGKB and a visual of the PharmGKB Knowledge Pyramid see Appendix A.

Figure 1. CPIC evidence level selection process flow chart
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Although several academic institutions have implemented preemptive testing and efforts
are made to provide guidance on how to use the test results, the challenge of implementing a
change in routine medical practice is a real issue. The complexity, size, and momentum to resist
change can stymie an innovation such as pharmacogenetics from clinical implementation. This
can even occur when the change is likely to lead to improved care. For the numerous positives
that have been researched and put forth by proponents of pharmacogenetic testing, there still
exist barriers to effective implementation. Work by the VUMC PREDICT program identified the
following challenges: "the assessment of the potential benefits for clinical pharmacogenomic
testing, definition of the target populations, designation of anticipated scope of
pharmacogenomic testing, determination of diagnostic methodologies, development of
infrastructure to support reporting, interpretation and use of results, and establishment of
reimbursement for testing."26
The focus of this research is to gain further understanding of the last challenge identified
in the previous list, "the establishment of reimbursement for testing." Third- party payers provide
a highly valued perspective on the challenges outlined in the VUMC PREDICT program. The
establishment of reimbursement policies for preemptive pharmacogenetics will be facilitated by
addressing the other challenges and a detailed look into the decision making process of the payer
should reveal some methods to move forward.

The Role of the Payer
The role of the payer cannot be understated in the adoption of pharmacogenetic testing as
standard of care. Third-party payers will need adequate evidence to justify coverage decisions
19

and provide the incentive for clinical practice to adopt this technology so that the potential
benefit to patients can be realized. Three types of policies are developed within a third-party
payer organization: the medical policy, coverage policy, and payment policy. The first is based
on scientific evidence and does not consider financial issues. The second is the most familiar to
the average person since it represents the contract between the purchaser and the issuer of the
policy and the scope of the benefits therein. The last is the policy between the issuer and the
practitioner that receives reimbursement for utilization of the service, in this case, the
pharmacogenetic test.
It is important to remember that coverage policies and reimbursement represent two
different things.38 Developing these policies requires studies from professional and academic
researchers to guide decision-making. The evidence required to build a medical policy is the first
barrier that must be overcome for pharmacogenetic testing to move forward. The specific types
of studies that payers desire has been ascertained by the research of Leung et al. and ranked
according to their importance as evidence: randomized clinical trials (RCTs), systematic reviews
(including comparative effectiveness research (CER)), review articles, professional society
guidelines, prospective observational studies, budget impact, cost and economic, and
retrospective observational studies.39 All of these score somewhere between a 3 and 4 on a 5
point Likert-type scale with the exception of the RCT, which received a score of 4.4. It needs to
be noted that the researchers found that the payers did not express concern for using
observational data from their own organization in coverage decisions.
Previous literature on how payers are approaching pharmacogenetic testing at their
organizations has revealed some fairly consistent themes with regards to the evidence payers
require when assessing a new health technology. A health technology assessment (HTA) is
20

research that is pursued, in this case, by a third-party payer organization, to assess the short- and
long-term consequences of the technology. The properties that are evaluated for new health
technologies are numerous: safety, efficacy, cost-effectiveness, ethics, legality, and politics. An
ISPOR publication identified five activities that define a formal HTA: horizon scanning, topic
determination, collection and assessment of evidence, appraisal, and funding and policy
implementation.40 The adoption of pharmacogenetic testing has been hindered by the third
activity, the collection and assessment of evidence, which ultimately hinders the last two
activities in the list.
The hindrance in this activity is not that evidence does not exist, but rather the type of
evidence that payers find useful in their evaluations does not currently exist. The diversity of
available genetic tests corresponds to the variability in how a payer will approach a coverage
decision and the strength of the evidence seems to be guiding the process. A study in 2010
examined six case studies of personalized medicine tests of varying types: disease
differentiation, pharmacogenetics, and genetic predisposition. They compared coverage
decisions among five large private and public payers and found that the pharmacogenetic tests,
with current evidence of observational genotype-phenotype studies, were not at all or not usually
reimbursed.6
Current coverage of disease diagnosis, risk, prognosis, as well as pharmacogenetic tests is
low. A study published in 2012 by Hresko and Haga using an online search of the top dozen U.S.
health insurers found that 18% of tests for disease diagnosis/risk/prognosis, and 30% of
pharmacogenetic tests, were covered. Thirteen of the twenty-seven pharmacogenetic tests that
were reviewed included an FDA drug label with pharmacogenetic information. The majority of
the pharmacogenetic tests were deemed investigational and not medically necessary. 3 The
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reluctance to reimburse seems to stem from three major concerns: a lack of clinical utility, tests
that are medically unnecessary (defined as lacking the FDA requirement of the test), and lack of
cost-effectiveness analysis and/or comprehensive comparative effectiveness analysis. 41
The expectation of clinical utility and comparative effectiveness is evidenced by the fact
that payers decline to pay for a pharmacogenetic test costing, many of which are less than $500,
while agreeing to cover drugs (for which the test could be used) that are much more expensive. 5
The difficulty assessing clinical utility in pharmacogenetics is exacerbated by the complexity and
burden of the randomized control trial, the evidence-based driven gold standard of clinical
utility. The requirement of a large cohort of heterogeneous patient populations, placebo effects,
and drug response variabilities frequently result in a small incremental clinical benefit. Lam
attributes this to the fact that pharmacogenetics emphasizes the safety and efficacy of outlier
patients, poor and ultrarapid metabolizers, as well as non-responders and those susceptible to
ADRs. Suggestions of clinical trials with smaller, targeted patient populations likely to respond
or not suffer ADRs have been one of the proposals to address the challenges of traditional RCT
assessment for safety and efficacy using pharmacogenomic biomarkers. Scientific and clinical
communities continue to debate the balance between the current required level of evidence of
clinical utility and those realistically achievable but still scientifically appropriate. 41
An in-depth investigation into the decision making process of six payers provided a look
past the basic need for clinical evidence. It examined policies around one genetic test, considered
a blend of diagnostic/risk and pharmacogenetics that has received coverage by all insurers, the
Oncotype Dx test to assess breast cancer recurrence risk and subsequently guide treatment
decisions.42 Four of the six payers indicated that they were willing to base their decisions on the
intermediate endpoint of clinical utility, defined as evidence the test affected clinical decision
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making. While the payers stated that they valued clinical effectiveness most highly, their
perceptions of its strength varied greatly. To help the payers overcome a lack of clinical evidence
in some instances, patient and provider adoption, of the penis fragment coverage by a California
Medicare Administrative Contractor (MAC), and endorsement of a medical society, along with
intermediate clinical utility, were considered as important health system factors in developing
policy decisions.
Although the Oncotype Dx did have prospective clinical trials, this exposé on the
decision-making processes of those who have adopted Oncotype Dx can provide other factors of
investigation when a new medical innovation may face uncertainty in clinical evidence. Further
study of variations among coverage policies for the technologies associated with precision
medicine might facilitate a more homogeneous adoption by educating the decision makers and
promoting less discontinuity among physicians and patients.
Slower payer adoption has affected the adoption of pharmacogenetic testing by health
care organizations, providers, and patients. Slow payer adoption can be attributed to three main
factors: lack of clinical trials to show the clinical validity of the test, little evidence that
pharmacogenetic testing has influenced clinical practice decision making and improves patient
outcomes, and whether pharmacogenetic testing is cost-effective to their plan. There have been a
few studies that have attempted to understand the third-party payer's point of view on this topic
through in-depth interviews. To our knowledge, no studies exist to capture the opinions of the
third-party payer with respect to preemptive pharmacogenetic testing.
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3. METHODOLOGY
Study Objectives
The study purpose is to investigate the perspectives and opinions about coverage and
reimbursement policies for preemptive pharmacogenetic testing of third-party payers. The
following objectives are to provide the necessary details to achieve the study purpose:
1. Describe the current policies third-party payers have on pharmacogenetic testing and how
these policies differ by the type of test
2. Describe the clinical evidence of effectiveness that third-party payers require for policy
decisions on preemptive pharmacogenetic testing
3. Describe the third-party payers’ perceptions of value with respect to pharmacogenetic
testing and the cost factors associated with preemptive pharmacogenetic testing coverage
decisions
4. Identify the practice/utility factors that third-party providers are using to make coverage
decisions for preemptive pharmacogenetic testing
5. Identify barriers and facilitators to third-party payer coverage of preemptive
pharmacogenetic testing.
Sample
Utilizing a payer panel made available by Medical Marketing Economics, LLC, thirdparty payers were invited to participate. No initial honorarium was offered to participants. A
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targeted final sample size of 15 payers was desired for the in-depth interviews, which is
consistent with previous work conducted in this area. 4,5 Interviews were conducted until
saturation of topic responses was achieved.

Data collection
Qualitative in-depth interviews were conducted via telephone, bookended by two
quantitative surveys administered online (Qualtrics, Provo, UT). A first invitation email (see
Appendix B) was sent to all members of the panel along with a brief online screening survey.
The screening survey asked about the participant’s professional capacity in their institution, size
of their plan, and the number of lives covered, as well as the breakdown of plan types for their
beneficiaries. The screening survey also assessed levels of familiarity, management, and priority
of health technologies and pharmacogenetics at the institution using several Likert-type item
questions. The screening survey concluded to assess respondents’ familiarity with preemptive
pharmacogenetic testing. The survey can be found in Appendix C.
Those respondents who answered "not at all familiar" on the question "Please rate your
level of familiarity with all types of pharmacogenetic testing” were not be eligible for the
interview. All eligible payers received a second invitation email (Appendix D), to participate in
the in-depth interview portion of the research. In the second email pre-read material was
provided to the participant and included descriptions of different types of genetic testing,
diagnostic, pre-symptomatic, and both reactive single-gene and preemptive multi-gene
pharmacogenetic testing. The work of the CPIC and PharmGKB on the clinical validity of the
drug-gene relationships that drive the actionability of pharmacogenetic testing was also
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presented to the participant. An example from the PharmGKB website
(https://www.pharmgkb.org/guideline/PA166128738) of the clinical decision alerts a clinician
might encounter based on the CPIC work was also provided. Non-responsive potential interview
respondents were sent a reminder email containing the same information one week after the
initial email.
The brief quantitative survey and discussion guide for the in-depth interview were
reviewed for face validity with a group of pharmacogenetic experts that have active involvement
in the use of these technologies, or are heavily involved in the academic research of
pharmacogenetics. After review, the guide and survey were updated to assure concise and
informative questions were presented. The first interview acted as a pre-test for the interview
guide used in the remaining interviews. Subsequent updates to the guide were made when
several questions were found to be unnecessary, and thus removed, while others were rephrased
to more accurately convey the intended questions. The interviews were digitally recorded for
analysis. Verbatim transcription was completed by a professional transcription service as the
interviews were completed. The semi-structured interview guide will be described in greater
detail below.
At the conclusion of the interview the participant was instructed to follow a web link to
complete a brief survey. This survey contained nine Likert-type questions that were originally
included in the semi-structured interview guide, but after the pre-test interview these questions
were deemed to function better as a stand-alone survey to summarize the conversation.
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Semi-structured Interview Guide
The interview guide has two sections: an introductory section and a section containing
three themes found in the pharmacogenetics literature. The first section contains seven questions
to assess the participant's attitudes toward pharmacogenetic testing more generally, including any
high level perceptions of the precision medicine and current policies they might have on different
types of pharmacogenetic testing. This number was reduced from 12 questions to 7 questions
after conducting the pre-test discussion/interview. The second section examines barriers to
further implementation of pharmacogenetics and key drivers of payers’ coverage policies with
regards to pharmacogenetics.2,4,5,10,39,40,41,43 It originally included 17 questions split among these
themes, but was also reduced to 14 and tailored based on face validity and pre-test discussions.
The specific pharmacogenetic themes covered in the second section of the interview
guide include: clinical utility and validity of pharmacogenetic tests, perception of value and cost
factors associated with pharmacogenetic tests, and coverage and reimbursement issues for
pharmacogenetic testing. The semi-structured interview guide can be found in Appendix E.

Data analysis
The results of the screening questionnaire were analyzed and responses to the surveys
were aggregated to obtain frequencies. This same information was parsed out for those payers
that were eventually interviewed (n=13, one did not complete the post-interview survey) and the
data are available in Table 1 and Table 2. A visual comparison was conducted to determine if
there were any striking differences among those survey respondents that agreed to the interview
and those that did not. An independent samples t-test was run to determine if there was any
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significant difference, between the respondents that were interviewed and those that were not, on
the items in the screener survey.
The qualitative interview portion of the study was analyzed as a content analysis. This
content analysis is a blend of inductive and directed (sometimes referred to as deductive)
strategies. As outlined in the description of the interview guide there were a number of preidentified themes introduced in the interview based on previous literature. However, respondents
were allowed to direct the conversation as they saw fit. More specifically, questions in each
theme were allowed to shift to another theme and new themes or subthemes were created if the
data strongly indicated such. The inductive research approach has been identified as the most
appropriate for relatively undeveloped areas of knowledge. 44 The blend of pharmacogenetics and
third-party payer opinions, underdeveloped and developed, respectively drove the decision to
pursue a blended qualitative research design. A decision was made to code and analyze the
transcripts manually instead of utilizing qualitative data analysis software. Although software
may save time and assist in the validity through increased rigor, this process can become
deterministic and focused inappropriately on the volume of data instead of the quality, distancing
the researcher from their data and potentially losing context and meaning. 45 With a topic focused
on an underdeveloped area of knowledge, this approach seemed inappropriate.
The transcripts were fully analyzed by the study lead and one other author to identify the
driving themes of the data. Each transcript was read three times by these two researchers. During
the first read through readers highlighted important statements made by the respondent and
provided a brief summary of the highlighted portion to identify the topic therein described by the
highlighted material. This is also known as meaning units. In a second read, the readers
identified codes from the first read through that appeared in a majority of the interviews and
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determined main themes and subthemes. A third read through was conducted to ensure no
important data were left undiscovered by comparing each interview to the themes and subthemes
identified. A third researcher was asked to mediate any disputes between the two other readers to
arrive at a consensus.
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4. RESULTS
The initial sample included 35 respondents to the screener survey. Six responses were
ineligible for any type of analysis due to incomplete responses leading to a final sample size of
29 respondents for the survey. As expected, payers were less familiar with preemptive
pharmacogenetic testing. Over three-quarters of respondents were somewhat, slightly, or not at
all familiar with preemptive pharmacogenetics.
Of these 29 complete respondents, 14 agreed to participate in the interview by responding
to follow-up emails. This consisted of nine pharmacy directors and five medical directors. Three
of the five medical directors proved more difficult to recruit and in an attempt to balance the
sample, a modest honorarium was offered to three medical directors.
Table 1 provides an overview of the demographics of the interview participants and
Table 2 provides data on the remainder of the questions from the screener survey. These 14
payers accounted for nearly 122,000,000 million covered lives or almost 40% of the U.S.
population. Plan size ranged greatly from 200,000 to as many as 50,000,000. These individuals
interviewed came from various types of organizations including: large traditional payers at the
national and regional level, national and regional pharmacy benefit management companies
(PBMs), group model health systems, individual medical groups that offer insurance, and
others. No two individuals interviewed were from the same health plan. However, some amount
of “double-counting” is possible between the PBM and traditional payers. Based on the visual
comparison of the data there did not seem to be any differences between those that agreed to the
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interview and those that did not. The independent samples t-test comparing the respondents in
the two groups did not reveal any significant differences. However, this t-test should be
interpreted accordingly due to the small sample size.

Mean

Standard
Deviation

Minimum

Maximum

8,708,898

15,815,280

200,000

50,000,000

Commercial PPO/POS (%)

47.5

35.8

0

100

Commercial HMO (%)

24.3

24.7

0

75

Medicare (%)

11.4

9.9

0

25

Medicaid (any) (%)

16.4

23.1

0

85

Other (%)

0.4

1.3

0

5

Length of time beneficiary stays with organization (years)

4.9

2.7

2

10

Demographics of interviewed payers (N=14)
Number of lives covered on plan

Table 1. Screener survey demographics
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Results of remaining screener survey questions for interviewed payers
Organization has official health technology
committee (N=13)
Organization as an adopter of new health
technologies (n=13)
Level of familiarity with all types of
pharmacogenetic testing

Level of management of pharmacogenetic testing
relative to other health plans (n=13)

Level of familiarity with preemptive
pharmacogenetic testing

Preemptive pharmacogenetic testing discussed at
P&T/medical technology meetings

Formal approach to covering preemptive
pharmacogenetic testing

Aware of clinical setting implementation of
preemptive pharmacogenetic programs

Yes
No
Not sure
Early adopter
Early majority adopter
Late majority adopter
Very familiar
Moderately familiar
Somewhat familiar
Slightly familiar
Highly managed
Moderately managed
Somewhat managed
Slightly managed
Very familiar
Moderately familiar
Somewhat familiar
Slightly familiar
Not at all familiar
Yes
No
Do not know
Yes
No, but in the process of putting
one together and will have one in
the next few years
No, and no current plans for the
future
Yes
No

% of respondents
50.0
42.9
7.1
7.1
28.6
64.3
7.1
35.7
42.9
14.3
7.1
28.6
28.6
28.6
7.1
14.3
28.6
28.6
14.3
23.1
64.3
7.1
15.4
46.2
38.5
15.4
84.6

Table 2. Screener survey non-demographic data

Content Analysis
The majority of interviews lasted between 30 and 45 minutes, however one lasted 75
minutes. All respondents were given the opportunity to review the material before beginning the
interview. The data from the interviews revealed three themes: clinical utility, economic utility,
and policy development. These correspond closely with the pre-categorization of the discussion
guide. Each of these themes had several sub-themes that will be discussed in detail below.

30

Clinical Utility – A world of potential with lacking clinical evidence
Payers believe there is potential value in having the pharmacogenetic data available for
clinician decision making, but remain skeptical that this data is currently providing evidence that
leads to better clinical outcomes for patients. This guiding idea on current clinical utility was a
major barrier for widespread adoption and coverage in the payer mind. This concern seemed to
come from a lack of objective outcomes level data:
"Now what needs to be tied to…is products A and C work better with this patient,
than product B and D for patient two based on the genetic profile as far as
outcomes improvement; survival, lower exacerbation, delay in correction, higher
level of control, duration medicine." Pharmacy Director #1 - Large National
Health Plan.
"If there's evidence...[the patient] should get preemptive testing, I'm willing to
consider that... Drug reactions are the number one problem and drugs that don't
work, drugs that cause more harm than good. I'm open to any of it, I just need to
see the evidence." Medical Director #1 - Large Regional Health Plan
Many saw pharmacogenetic testing as something that would become standard practice when
prescribing medications in the future, but expressed doubts it was going to become pervasive in
the next five years.
There were four sub-themes identified under the main theme of clinical utility: potential
value of pharmacogenomics, CPIC and actionability, types of clinical data needed, and testing
versus monitoring. The “potential value of pharmacogenomics” was asked explicitly to some
participants while others offered up their opinion without prompt. Adding to what was
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aforementioned; payers see potential value to both patients and the health system but remain
apprehensive.
"Tremendous potential, tremendous potential to help us much better refine who
we give drugs that often have to be targeted for large populations with a fair
amount of variability and drug response. But that being said, at the present time
they are relatively low on the value scale." Medical Director #2 - Drug Benefit
Collaborative with medical policy management
Value was also subject to the type of pharmacogenetic testing payers were using as a basis for
their answer. While germline pharmacogenetics, and the pharmacokinetic and pharmacodynamic
properties affected by genetics, was the focus of the interviews, payers frequently referred to the
companion diagnostics associated with cancer drugs because they were more familiar with them.
In fact, several payers made it clear that they desired a test that would provide them with yes or
no decision on the reimbursement of a test, “We're looking for a test where we can make the
physician accountable, either a yes or a no. Not something that there is a 70% likely response
versus a 40% likely a response” Medical Director #4 - Large National Health Plan. This led to
the observation that many payers were unaware of pharmacogenetic testing outside of scope of
companion cancer diagnostics, and as such their expectations were somewhat out of step with the
information these tests could provide.
The second subtheme, “CPIC and actionability”, focused on payers reactions to the work
of this organization and how the data it generates could be used in pharmacogenetics.
Interestingly, almost all payers were unfamiliar with CPIC and PharmGKB and the
corresponding rating scales and guidelines being developed and payers were pleasantly surprised
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by the work being conducted. However, the previous discussion about the ability to make a yes
or no decision based on these tests was reiterated in responses to the perceptions of CPIC.
Multiple payers used the term "gray area" to describe the lack of clarity on making a yes or no
decision with these tests.
"The challenge is if it’s A, then can I say, yeah, it should be built in policies; if
it’s D, then I’m gonna say I’m not gonna cover this. But if it’s B or C, I can’t
make a – I can’t enforce a decision or a policy around that. So, no, this is – it
might help physicians guide, but, again, it’s a guidance and it’s not something that
a payer can definitively use to make a decision on. That’s the challenge."
Pharmacy Director # 5 - PBM w/ medical policy
Given the lack of current use in coverage decision-making, CPIC guidelines were viewed mostly
favorable in the context of their incorporation into the electronic health record (EHR).
Interviewees felt that CPIC could provide incremental benefit by guiding prescribing.
"If you have a particular drug where a test said this (medication dosage) needs to
be reduced, this is not just based on – I would speculate to say that this is
compelling data. Those things can be built in as alerts. The electronic record,
dysfunctional as it is, can be useful for that." Medical Director # 3 - Medical
group offering insurance
An unprompted discussion also occurred with several payers on the similarities of CPIC
with others such as the National Comprehensive Cancer Network (NCCN) guidelines for cancer
treatments. Payers communicated that expanding the breadth of their (CPIC) work could increase
their credibility, but stopped short of saying they would reimburse based on these guidelines.
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"They (NCCN) started creating interest as far as should you cover this, should
you not cover that, we rate this one a 2A, we rate this one a B. They have
different ratings for the drugs. That really hadn't happened in a long period of
time at all. I think that, that model could be used in something like this." Medical
Director # 3 - Medical group offering insurance
The next sub-theme “clinical data” specifically focused on the kinds of clinical data that
would be useful to payers and stemmed from previous literature suggesting that the RCT may be
an unnecessary financial burden, particularly for previously approved and post-marketed drugs.
These discussions provided a wide array of responses:
"I quite frankly do think you need the randomized control trials. Those clinical
reports may be helpful. If you're going to do this, it really depends on the disease
process in terms of that. You have to establish an outcome." Medical Director #4
- Large National Health Plan.
"You almost wonder if the best way to do this is in some kind of real-world type
of population based study where you test a large group of people and then look
retrospectively to see if you can then document a rationale for maybe a drug
problem or a failure to respond they had in the past." Medical Director #2 - Drug
Benefit Collaborative with medical policy management
The number needed to “test” or NNT calculation was a topic frequently brought up by
payers without any explicit mention of the topic. A NNT is traditionally known as “number
needed to treat” but in this case, interviewees shifted it to be number needed to “test”. More
specifically payers defined this as the number of pharmacogenetic tests needed to be
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administered to avoid one additional adverse outcome. Payers made it clear that this was
something that physicians, and themselves, will use frequently when evaluating the utility of a
new treatment or technology.
"You know, again, like anything else, if five percent of the patients are avoided, I
don't know if it's worth it. If 40 percent have a drug change or are avoided,
depending on the cost of the test, it may be worth it. So, it's going to be the
number needed to test, sensitivity, specificity, actionability." Medical Director #5
- Large Regional Plan
Some payers also questioned the notion that doing an RCT on only patients who are known to
respond would only help those patients, citing a potential benefit for other patients where the
drug works but maybe just not as well.
The last subtheme, “testing vs. monitoring”, under the main theme of clinical utility was
more inductive in nature as it developed naturally from many of the discussions with
interviewees. The debate was one that compared the standard of care for clinical prescribing;
dosing and administering one product and waiting to see how the patient responds and if changes
need to be made the physician adjusts and waits again, to the use of a preemptive
pharmacogenetic test (or reactive) to guide potentially more accurate initial dosing…"If it’s a
very low cost drug you know, you try one and then maybe try another. Because one of the
concerns was some of the testing is that it’s going to lead you to maybe pick first line."
Pharmacy Director #6 - Large National Health Plan
This quote shows how payers viewed this testing through the lens of cost by type of drug.
Again, the tests payers were most familiar with were the companion diagnostics for high priced
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cancer drugs where no generic or low cost alternative exists. One payer challenged the
applicability of preemptive pharmacogenetic testing and its benefit to patients by being available
in the EHR at the time of initial prescribing...
"The question is, is that test going to delay intervention? We are waiting for the
results. How long does waiting two or three days or a week for test results really
going to impact outcome? So I don't know. I don’t know that I am too concerned
about the length of the test - or how long it would take to get the results of a
particular test." Pharmacy Director #7 - Large Regional Health Plan
Economic utility – The cost burden of organization wide testing and issues in calculating
downstream economic benefits
The importance of pharmacoeconomic research in this space is important, most likely as
a result of the large upfront costs of widespread testing. Economic utility in healthcare typically
refer to cost utility analyses and are considered in concert with a demonstration of clinical utility.
There are no subthemes under this major theme as the discussion focused on the topic of the
costs of widespread testing and what potential cost offsets could be realized from testing. The
payers’ familiarity with cancer diagnostic pharmacogenetic tests again seemed to guide their
perspectives on this discussion. For example they cited a willingness to pay for a test that costs
several thousand dollars when associated with an extremely high priced cancer drug.
"Okay, I'll spend a few hundred dollars or even a couple thousand dollars on a
genetic test if it tells me the best way to handle a $100,000 a year anti-cancer
therapy. That's a no-brainer. Now, let's think about pharmacogenetic testing that
you're going to apply to large populations. Theoretically, you don't have to do it
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multiple times... Let's say it's even a ridiculously low, low price of 100 bucks. If I
got a million members that I got to test, I just spent a (hundred) million dollars
and I don't know what my return on that investment is going to be." Medical
Director #2 - Drug Benefit Collaborative with medical policy management
As evidenced by this quotation, payers are either unaware or do not have the sufficient
data that the potential economic utility behind the preemptive is the ability to avoid adverse drug
events, and subsequent hospitalizations and additional medical procedures. As such the payers
were probed on this subject. Still the payers can only conceptualize this idea because of a lack of
exposure to that data.
"...if you are going to identify a responder knowing full well that six weeks down
the road they may switch to something else, but now you know they are not
because you know they are going to respond then yeah I could see some cost
savings associated with that...If you know that patients are going to not develop a
certain adverse event and therefore going to be more compliant on their therapy
because it is better tolerated or they don't have to be hospitalized,... again I see
that more as a cost benefit; but downstream though." Pharmacy Director #7 Large Regional Health Plan
This perception of downstream costs being prevented was something that payers valued, but at
the same time they find using these cost offsets difficult when making coverage decisions.
"Would we focus it on where we had potential risks either in preventable
admissions or hospital readmissions and have offsets? Yes. I think when it trickles
down through all that triage, to what’s good for society and good for the patient to
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get an earlier experience, I’m (going to) suggest probably funding and resources
run out before we get to that level of compassion and empathy. Ideally, I think
that’s great, but I don’t think that’s real world." Pharmacy Director #6 - Large
National Health Plan
Payers have demonstrated concern that testing large numbers of people will most likely strain
their organization. Although they also speculate that they might realize some cost benefit in
avoiding additional medical services from testing, the costs are secondary or downstream in
their prioritization. They currently lack the information needed to predict how patients will use
this technology, and thus the ability to make an accurate decision on who to cover.
Many payers also had concerns about potentially large upfront cost of the preemptive
technology. To investigate this, payers were presented with a hypothetical price scenario in
which a multi-gene preemptive pharmacogenetic test was double the cost of a single-gene
reactive pharmacogenetic test, $500 versus $250. They were asked to consider whether that price
difference was enough to deny reimbursement of the more expensive test if ordered by a
physician to guide drug selection. All but one payer that was asked to speculate on this scenario
concluded that the price difference was not large enough to deny reimbursement of the $500 test.
"That's a good question. I think again the answer is yes because again, we're not
selecting a small subset of the population saying, "Okay, on this subset I'm going
to do the $500 test instead of the $250 test." You're committing yourself to doing
a fairly substantial expense on a large number of patients. The problem you're
going to run into there is again a big upfront cost for unknown value down the

38

road." Medical Director #2 - Drug Benefit Collaborative with medical policy
management
This scenario was proposed to the payers as a hypothetical to investigate whether current
approximate price differences between multi-gene and single-gene tests were substantial enough
to affect decision making. The answer appears to be that it is not, and this might allow for some
slow integration of multi-gene testing into the system.
Policy development – Population health and the role of other influential stakeholders
Influence from other stakeholders coalesces to provide the payer with another level of
considerations beyond just clinical and economic data when evaluating pharmacogenetic testing.
The policy development theme evolved from a variety of topics that contributed to the payer
decision-making. Numerous subthemes were identified; many of these were drawn from an
explicit line of questioning including the effect of CMS and the FDA on third-party payer
policies, the stratification of beneficiaries receiving pharmacogenetic testing, and the role of
active preemptive pharmacogenetic implementation.
The first subtheme “population health” developed more implicitly due to several
particularly interesting conversations examining the potential utilization of preemptive
pharmacogenetics as a standard preventive health screening. A recommendation from the U.S.
Preventive Services Task Force was discussed as a potentially influencing widespread adoption
and coverage of preemptive pharmacogenetics.
"The other way it could be is all plans and payers have annual refreshment and
linkage to preventative health guidelines in quality metrics when it’s used... If it
ever became a part of an annualized preventative health guideline, published and
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adopted and/or became a quality metric that will help you, then it would become,
and we would pay for it." Pharmacy Director #9 - Large Regional Health Plan High proportion of Medicaid beneficiaries
The concerns being communicated with regard to the high cost of organization or population
wide testing, as discussed previously, allowed a probe into potential considerations to attenuate
this barrier.
In light of the difficulties with population health widespread adoption, payers were asked
to speculate on if they would consider the stratification of beneficiaries to those over a certain
age or those with co-morbidities increasing their need for certain pharmaceutical products. This
was met with variable response as some payers were willing to consider this as a possibility,
while others found it difficult and potentially unethical to choose which beneficiaries might be
offered such a technology.
"I think that if you have a patient that's 60 years old and they're relatively healthy,
you may have already done this but you may decide that at that age 60, it's time
that he has or she has this information in his file so the $500 gets spent. I think
that's going to be really up to the physician on how they view the patient. But I
don't think we are going to go out and promote a multi-gene testing for everybody
over 65 or everybody over 60 just because the consortium or the guidelines or
whatever say that is the right patient for these." Pharmacy Director #2 - Regional
Health Plan
"I don't think that we would ever do anything like that. I do not think that would
be anything legal would ever allow... "Well, if you have these underlying
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conditions then you can do a preemptive." If you don't, "Eh, so sorry. Until we
develop something, we're not going to test you."... If there was requirements or
guidance along those lines, then plans of course would be obligated to comply.
That's more or less government taking a stand now." Pharmacy Director #4 Large National Health Plan
The diversity in response to this question again demonstrates the level of uncertainty in this
space. In concert with other levels of evidence, payers may be looking to an organization such as
CPIC to provide them with information on patient types at a more granular level. One payer was
particularly adamant about this concept...
"I think the consortium should really - and again I don't know if that is the intent
of what they are trying to do, but I think the consortium should come together and
say who should be eligible. At least not just the level of the test itself, but what
type of patient, what level of risk, age and things like that." Pharmacy Director #7
- Large Regional Health Plan
Payers were probed on the level of influence that the Centers for Medicare and Medicaid
Services (CMS) would have on how they went about developing policies for these technologies.
As a starter to this conversation, payers were asked if they would consider doing a type of pilot
study that CMS has used called "coverage with evidence development". This program allows
products or services to be covered by CMS only in the context of an approved clinical study.
These studies are conducted when CMS believes that evidence does not support coverage outside
of the context of one of these well-designed clinical studies. Payers had mixed reactions to this
type of program and the implementation with their own data. Some spoke highly of it and the
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potential for CMS to disseminate their findings to the larger payer audience, “Very likely as a
pilot we would look at something like that. We do a lot of pilots in conjunction with CMS."
Pharmacy Director #2 Regional Health Plan
Other payers would find the results of such studies from CMS valuable, and instinctively follow
their lead...
"I think the learning from that kind of a program probably translates more into the
potential that at some point down the road, the tests become part of the things like
system pathways or guidelines…we've used CMS actions in the past that changed
how we price drugs. I think we could certainly adapt our coverage criteria to if it
becomes a standard of care..." Pharmacy Director #8 - Regional PBM
The influence of CMS decisions was an undeniable force in the wider adoption by the payers
interviewed in this current research. Payers also stressed the impact that a Federal Drug
Administration (FDA) approval of pharmacogenetic tests and inclusion on FDA product labels
has on coverage decisions. A FDA label that includes a pharmacogenetic test provides
substantial evidence to payers that the test provides an additional level of benefit to a (certain)
patient above the drug itself. Some indicated that it would be an absolute necessity to have FDA
labeling to be considered for reimbursement, "I think it's still going to have to be approved by the
FDA. It has to be part of the product labeling. You don’t see too many other ways around that."
Pharmacy Director # 5 - PBM w/ medical policy
The requirement of product labeling seems to be driven, in part, by the demonstration of efficacy
for products designed for a specific mutation, predominantly somatic.
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There was skepticism from several payers on the willingness of the pharmaceutical
industry to support pharmacogenetic testing. The skepticism was based in the view that the
industry does not realize as much a financial benefit from the sale of drugs in a smaller, more
directed population.
"You would think that the pharmaceutical company would come out with it but
they don't because they want it to be used in everybody and not just specific
patients." Pharmacy Director #2 - Regional Health Plan
Tying in the previous subtheme and role of the FDA, one payer provided an interesting insight
into future drug development...
What we're hoping to see…before the drug even is allowed to come to market, is
suggesting or I guess requiring that manufacturers have some sort of companion
diagnostic or predictive test that's going to show whether the drug will work on a
given patient. Then, you could probably price your drug more predictably with the
expectations of success. I would think they would be in favor of it. Pharmacy
Director #8 - Regional PBM
Payers also showed some inherent concern that if a pharmaceutical company were to go about
developing drugs in much smaller patient populations that they would naturally raise prices to
compensate for the lost revenue from treating fewer patients.
"I think they're going to be very cognizant of it as a concern we all have of drugs
that are targeted. Having drugs available for small target populations notoriously
meant much more expensive so that the cost savings by targeting the drugs may
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disappear because the drug prices will go up." Medical Director # 3 - Medical
group offering insurance
To close out the policy development section, payers were asked about the information
presented in the pre-read concerning the active implementation of preemptive pharmacogenetics,
the last subtheme. Most payers were pleased that these academic centers had endeavored to
pursue this implementation as most were positive on the future for this technology.
"I'd also like to see their data and how it's made a difference, and what specific
entity, what diseases they treated, and what were the outcomes based on the
choices that they've made. If you're going to proactively do this, tell me what your
physicians did with that information. Did they actually change the medication, did
they alter the dose of the medication, what were the outcomes, and was the patient
discharged sooner or having a shorter length of stay?" Medical Director #4 Large National Health Plan.
Payers believe these institutions can potentially provide a great deal of real-world data on
meaningful outcomes that come from the implementation of such programs.
At the conclusion of the interviews, a brief survey was administered using nine likerttype items on a scale of 1 to 5, 1 = strongly disagree and 5 = strongly agree, to summarize some
of the major concepts and drivers of payers perspectives on coverage of preemptive
pharmacogenetics. All but one payer responded to the survey. The full results of this survey are
found in Table 3 below.
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Post-interview survey results on five-point Likert-type items (1 = strongly disagree
to 5 = strongly agree)

Average score
(n=13)

FDA labeling of pharmacogenetic information on approved drugs will impact my coverage
decision.

4.6

Clinician adoption and the endorsement of medical societies for preemptive pharmacogenetic
testing is/will be an important factor when developing coverage policies.

4.5

Pharmacoeconomic data and the demonstration of cost-effectiveness is/will be important in
determining coverage decisions for preemptive pharmacogenetic testing.

4.4

Clinical value is/will be added when clinicians have access to pharmacogenetic data in the
electronic health record (EHR) at the time of diagnosis and prescribing.

4.3

Adoption by CMS and other third-party payers would influence my organization to likewise
develop coverage policies for preemptive PGx testing.

4.2

The clinical validity of the gene-drug pairs determined by CPIC makes pharmacogenetic testing
more actionable for clinicians

3.8

The influence of preemptive pharmacogenetic testing on clinician decision-making is/will be an
important consideration when evaluating coverage decision.

3.8

Preemptive pharmacogenetic testing will provide greater clinical value to the patient and clinician
by testing hundreds of genetic variants prior to prescribing.

3.5

The constructing of reimbursement policies for preemptive pharmacogenetic testing is likely to be
burdensome.

3.1

Table 3. Post-interview survey results
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5. DISCUSSION
The examination of the third-party payer’s perspectives on preemptive pharmacogenetics
provided a diversity of viewpoints on several important topics with which the pharmacogenetic
research community should be actively following. The proliferation of more objective outcomes
studies from the use of pharmacogenetic testing is the desire of most payers. There is energy
from many of these individuals that healthcare and researchers should pursue this, but they cite
an inability to make decisions hampered by insufficient evidence. The economic perspectives,
particularly on preemptive pharmacogenetics, focused on budget sustainability from widespread
organization testing. Not only was the cost from large scale testing a concern, but the difficulty
in predicting any potential downstream cost benefits was an issue. Although many payers
speculated that the benefits were a real possibility, the ability to integrate that into coverage
policies would prove difficult. Third-party payer decision making processes are driven by a
myriad of forces including the role of both public and private entities. These forces produce an
interesting layer of influence that should be considered in conjunction with clinical and
economic data.
The stress placed on the development of further evidence of clinical utility was first and
foremost with many payers. Many payers speculated on the future delivery of healthcare and
how they thought this technology fit in, but they remained pessimistic on the timeline with which
preemptive pharmacogenetics would see widespread adoption and utilization. The American
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Society of Hospital Pharmacists (ASHP) 2016-2020 Pharmacy Forecast found that those
pharmacists survey believed that 51% thought it very likely or somewhat likely that pharmacists
in at least half of health systems will be providing treatment recommendations based on
pharmacogenetics by 2020.46 A recurring sentiment was that preemptive testing, or even
germline testing more broadly, did not provide the payer with the appropriate information to
make a coverage decision, in contrast to the somatic testing that targets specific mutations within
the cancer. This is an inherent difference between cancer companion diagnostics and single-gene
or multi-gene germline pharmacogenetic testing, and their use to the payer. Payers desire the
"go" or "no-go" indication from a test, but germline testing provides a broader range of data
covering multiple pharmacogenes and associated drugs in the case of multi-gene testing. The
actionability of these results do indeed point to instances where the drug being administered
should be replaced by another drug, in line with companion diagnostics, but in many cases this
testing leads to the more accurate dosing of pharmaceuticals to avoid adverse events, and thus a
decision to cover the drug in question or not would be nearly impossible.
This cautiousness or pessimism, in part, may stem from a lack of understanding in the
developing field of germline pharmacogenetics and corresponding relevant evidence. The work
of CPIC stood out to most payers as a positive step toward improving utilization. Payers found
CPIC’s work encouraging and similar to NCCN guidelines. Payers continued, however, to refer
back to the idea that they need information that informs a “yes” or “no” decision to test. This is
something that the NCCN guidelines contain, likely a reason for their belief and hope that CPIC
would do the same. Language in the NCCN guideline for gastric cancer strongly recommends
HER2 testing for those with metastatic disease at time of diagnosis.47 Payers believe that
providing guidance on prescribing and inputting this information in the EHR was positive, but
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not specific enough to guide policy making. However, the current mission of CPIC is not to
provide guidance on “when” or “who” should be tested, but rather what providers and patients
should do with the results of the tests.
Payers want to see real-world outcomes data from patient populations or randomized
control trials. When probing payers on the types of data they needed, a mix of responses ranging
from only clinical trials to retrospective studies came out. Most wanted some sort of prospective
design where the patient could be followed. The Brixner study described previously that used a
prospective cohort propensity score matched to a historical cohort could serve as a
methodological model for researchers outside of a traditional RCT. 21 Payers control vast
amounts of patient data and have the opportunity to pilot pharmacogenetic testing rather
efficiently if needed or desired. However, payers had mix responses when asked if they would
pursue something of this sort, as CMS did in their “coverage with evidence development”
program. There was clearly no consensus on proactively moving into these types of studies.
Prospective studies could answer two questions that payers found to be crucially
important: what is the benefit of testing and treating over treating and monitoring? And what is
the number needed to “test” to realize a benefit in one patient? The first question stems from the
assumption that using a potentially expensive test to dose very inexpensive generics, or having
the test produce results showing that the patient should be administered a more expensive
treatment first-line, without consideration of a cheaper generic, would ultimately lead to higher
health care costs for the system. Advocates of preemptive pharmacogenetics would argue that a
higher cost pharmaceutical (compared to a drug of lower relative cost) might actually be a costsaving pharmaceutical because of its precision with the patient in question, thereby avoiding
potential adverse events or numerous try and fail strategies with other medications. Large
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prospective studies would provide the evidence needed to answer this question and the objective
outcomes payers desire.
Answering the number needed to “test” question would provide an objective figure with
which to evaluate specific pharmacogenetic tests. This type of data is particularly important for
preemptive and germline pharmacogenetics because part of the benefit from this technology
comes from avoidance of adverse events and potential re-hospitalizations. According to the
interviewees, both physicians and payers find value in this type of information. Member
hospitals of the PGRN community are implementing preemptive pharmacogenetic programs and
have the opportunity to present information that could help answer some of these pressing
questions. Current implementations of pharmacogenetics in clinical practice might be providing
enough data to begin calculating NNT's within their patient populations. 1 Recent work by Tonk
et al., describes some appropriate methodologies to evaluate measures of population impact from
pharmacogenetic tests including the NNT, as well as a population attributable fraction (PAF). 48
The PAF indicates what proportion of adverse events would be eliminated if patients carrying a
variant received a different treatment. These types of data provide strong assessments of clinical
validity by predicting adverse events and its impact on broader population health.
The conversation around cost with the payers was consistent and focused on the cost of
testing large swaths of the population, the associated upfront cost, and the unpredictability of
downstream cost savings. Once again, payers used the cancer companion diagnostics to frame
their responses. It was an easy decision for payers to spend several hundred or a few thousand
dollars on a test for a drug that cost upwards of six figures, but outside of that it became much
more tenuous. Payers indicated little focus on the actual downstream costs associated with
preventing adverse events and re-hospitalizations. The variability in how payers evaluate
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downstream costs is likely driven, in large part, by the type of organizations. Many traditional
insurers indicated a one year time-frame for evaluations of costs, utilizations, and benefits.
Recognizing how preemptive pharmacogenetics postulates its benefit, this time-frame of
economic evaluation is unlikely to lend itself to positive conclusions. Those from more
integrated systems, meaning some higher level of coordination among providers and payers,
appeared more willing to move toward preemptive testing.
Stronger assessments of this information might facilitate the adoption of
pharmacogenetics into those with value-based purchasing structures looking to avoid ineffective
care.4 Concerns with when a patient and physician would actually use the data, and what cost
offsets might be realized, was another reason for caution as payers evaluated this use. Most of
the products or interventions presented to payers for evaluation are designed to address a
particular disease state or certain condition, and thus can be prescribed in a treatment plan after
an official diagnosis. Preemptive pharmacogenetics demonstrates its value prior to diagnosing
and prescribing, but sometimes with an unknown time frame for utilization, and thus presents a
challenging assessment of cost tradeoffs. Reactive pharmacogenetics alleviates the concern of
paying for a test whose results might not be used for years, but the reach of most reactive tests is
usually limited to the single pharmacogene in question for the treatment being prescribed and
will likely be not be cost-effective as the price of all types of testing continues to drop. Relling
and Evans note this coming crossroad when a decision must be made between a test that is
ordered for one gene because of immediate actionability on a diagnosis and a test for genes that
includes the former, but also provides genetic information for future diagnoses.2
To probe the topic of large upfront costs further the payers were asked to consider if they
would stratify beneficiaries based on age or number of co-morbidities. This was also met with
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variable response and hesitancy due to potential ethical or legal issues. However, the use of pilot
programs as discussed previously might provide useful prospective information on what types of
patient cohorts are benefiting the most from preemptive pharmacogenetic testing. If payers
remain apprehensive to the widespread adoption, a strategy such as this could prove useful to
gradually increasing the number of patients with pharmacogenetic data loaded into their EHR.
However, this could be limited by the type of clinical decision support system employed at the
site of care and subsequent usability of the data.
The conversation that implicitly developed and was suggested by several payers
concerning the adoption of pharmacogenetic as a preventive health technology endorsed by the
U.S. Preventive Services Task Force (USPSTF) was particularly interesting. Some payers
suggested that achieving coverage through this course of action was more appropriate for this
type of technology, although citing the stringent approval process. However, this is not
completely unrealistic. The USPSTF is an independent body that was convened by the Agency
for Healthcare Research and Quality. 49 Recommendations are frequently met with opposition
from various clinical groups due to impacts on current practice. For example, a series of
exchanges between editors and readers of the journal Radiology in 2010 demonstrated strong
opinions and dissent on the change in recommendations of appropriate age for regular breast
cancer screenings.50 It is likely that something such as preemptive pharmacogenetic testing
would be met with a similar form of resistance.
The number of preventive services covered expanded with the implementation of the
Affordable Care Act in 2010. Some of these services are one-off screenings but many may
require recurring screenings to work effectively. Multi-gene pharmacogenetic testing could
potentially provide a screening with utilization for an indefinite time period, and thus not require
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any re-screening. However, it is likely that even the largest multi-gene pharmacogenetic test will
at some point in the future require expansion as more gene-drug relationships are discovered year
by year. Whole genome sequencing would ensure the complete mapping of relevant
pharmacogenes, but the current widespread implementation of this would be economically
untenable.
The impact of CMS was briefly mentioned previously with regards to the “coverage with
evidence development” but it is worth noting that payers do stay abreast of policy decisions from
CMS and will make many of their own decisions in line with them. Payers also mentioned the
importance of pharmacogenetic tests being included on the FDA label. When considering the
functionality of a preemptive multi-gene pharmacogenetic test for germline mutations, making a
coverage decision based on FDA labeling will likely be a more nuanced processed. Almost 200
drug products driven by known pharmacogenes already contain pharmacogenetic data as part of
their approved FDA label. Many of these labels, however, do not require pharmacogenetic
testing for approval as we have seen in oncology drugs targeting a specific mutation. Again, this
demonstrates the payer difficulty in dealing with the disconnect between the obvious yes or no
decision and the presentation of pharmacogenetic data in the label as it applies to dosage and
administration, precautions, use in specific populations, and adverse reactions. The inclusion of
pharmacogenetic data on the majority of FDA labels, outside of the oncology space, does not
provide payers with the appropriate level of evidence to make a similar decision. Exceptions
include the drug abacavir, which can lead to a fatal hypersensitivity reaction in some patients,
specifically mentions screening for the HLA-B*5701 allele before dose initiation.33 Other
medications such as clopidogrel, which has strong clinical support for diminished antiplatelet
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effect in some patients, contains a boxed warning but does not specifically require testing prior to
administration.
The evolution of policy development for pharmacogenetics is going to be an ongoing and
fluid process, requiring tremendous input from sources both private and public. Truly widespread
adoption of pharmacogenetic testing will require the work of academic researchers in
communities such as PGRN and CPIC to provide that next level of evidence to guide policy
decision making.

Future directions
The findings from this study provide the pharmacogenetic research community with
several avenues for potential research opportunities. A greater number of prospective real-world
population studies testing the impact of preemptive pharmacogenetic testing on measurable
outcomes will provide the strongest evidence to facilitate greater adoption. This approach must
also include an assessment of those “downstream” costs that payers referenced several times.
This type of analysis is not top of mind for many of these decision makers, but as we move more
towards value based healthcare, the importance of this type of data will become ever more
relevant. Wade et al. stress the importance and role that genomic programs have in developing
value-based and patient-centered healthcare.7 Several aforementioned methodologies have been
described to evaluate pharmacogenetic tests in a manner that produces data that will be of greater
interest to payers and policy decision makers, and should be pursued accordingly. Detailed and
speculative economic modeling of the pharmacogenetic tests can provide an assessment of
potential costs that could potentially be avoided. The granular identification of these costs can
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then be applied to real-world studies improving the applicability and dissemination among
various care settings.
Several opportunities exist to explore pharmacogenetics role in future health policy.
Studying the potential role of the U.S. Preventive Services Task Force would serve as evidence
for broad implementation of preemptive pharmacogenetics as a population health policy. Also,
the shift towards value-based reimbursement structures might facilitate the adoption of more
preventive measures and increase the reach of preemptive pharmacogenetics.

Limitations
The respondent self-selection to participate in the screener survey may suggest that they
are more familiar with pharmacogenetics than the average third-party payer, or that their interest
might bias their responses in some way. Although this bias would be impossible to ascertain, no
biases were identified between those respondents who agreed to participate in the interview and
those that did not when comparing responses on the screener survey. Comparability of data may
have been reduced due to the different wording and sequencing of each interview. However,
richness is gained through this by allowing each interview to gain its own coherence. Qualitative
data always come with a question of the level of truth. In this case respondents had no incentive
to provide responses that were anything other than accurate. It would be difficult to imagine a
scenario in which the respondent personally benefited from providing untruthful data.
Conclusion
Third-party payer opinions of preemptive pharmacogenetic testing indicate a cautious
optimism. Concern over the lack of objective outcomes available, an inability to assess economic
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benefits, and the potential high costs from widespread testing are the central reasons for this
caution. Payers are, however, encouraged by the efforts of organizations such as CPIC that are
making the data that is available more actionable and the consortiums that are implementing
pharmacogenetic interventions in real-world populations. Expanding reimbursement and
exposure of pharmacogenetics to the medical professions should facilitate greater physician
adoption and provide further opportunities to study associated outcomes in meaningful ways.
This study should be viewed as a call to advocates in the pharmacogenetic research community,
both clinically and socially, to continue the pursuit of work directed at addressing the needs
described within.
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Clinical Annotation Levels of Evidence1
1A Annotation for a variant-drug combination in a CPIC or medical society-endorsed
PGx guideline, or implemented at a PGRN site or in another major health system.
1B Annotation for a variant-drug combination where the preponderance of evidence
shows an association. The association must be replicated in more than one cohort
with significant p-values, and preferably will have a strong effect size.
2A Annotation for a variant-drug combination that qualifies for level 2B where the
variant is within a VIP (Very Important Pharmacogene) as defined by PharmGKB.
The variants in level 2A are in known pharmacogenes, so functional significance is
more likely.
2B Annotation for a variant-drug combination with moderate evidence of an association.
The association must be replicated but there may be some studies that do not show
statistical significance, and/or the effect size may be small.
Annotation for a variant-drug combination based on a single significant (not yet
3
replicated) or annotation for a variant-drug combination evaluated in multiple studies
but lacking clear evidence of an association.
Annotation based on a case report, non-significant study or in vitro, molecular or
4
functional assay evidence only.

1

PharmGKB: www.pharmgkb.org
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APPENDIX B – FIRST INVITATION EMAIL FOR SCREENER SURVEY
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Good Morning,

I hope this email finds you well. I have a research opportunity I think you would be interested in.

The research will be conducted in two parts, between the dates of April 27 - May 18. It will
cover preemptive pharmacogenetic testing.

This portion of the research includes a brief online survey that will take approximately 5 minutes
to complete. This research is being conducted for academic purposes so we will be asking some
questions to ensure alignment with the research objectives.

Please follow the link below to begin the survey.

<<<qualtrics link>>>

Thank you.
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APPENDIX C – ONLINE SCREENER SURVEY
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Thank you for your participation in this research. You will be required to answer all
questions but you may withdraw at any time. Your name and institution will always
remain confidential.
By completing the survey/interview you consent to participate in the study.
1. Are you at least 18 years of age or older?
o Yes
o No (not eligible to continue)
2. Are you a...?
o Medical director
o Pharmacy director
o Other, please specify _________
3. Approximately how many lives are covered on your plan?
4. What percent of your covered lives fall into each plan type?
%
a. Commercial PPO/POS
b. Commercial HMO/IPA
c. Medicaid (any)
d. Medicare
f. Other, please specify___________
SUM = 100%

5. What is the average length of time a beneficiary stays with your organization?
6. Does your organization have an official health technology committee?
o Yes
o No
o Unsure
7. If answered yes to Q7....have you served on this committee?
o Yes
o No
8. How would you rate your organization relative to other health plans regarding
adoption/coverage of new health technologies?
Laggard
o

Late majority
adopter
o

Early majority
adopter
o

Early adopter

Innovator

o

9. Please rate your level of familiarity with all types of pharmacogenetic testing.
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o



Pharmacogenetic
testing

Somatic pharmacogenetics - Identification of acquired genomic
variants that influence response to drug , this type of
pharmacogenetics is mostly relevant in malignancies to guide the
choice of anticancer therapy
 Germline pharmacogenetics- Identification of inherited genomic
variants that influence alterations in a drug's pharmacokinetic and
pharmacodynamics properties
Not at all
Slightly
Somewhat
Moderately
Very
familiar
familiar
familiar
familiar
familiar
o
o
o
o
o

10. Do you currently cover any pharmacogenetic tests or have you reviewed any in the past?
o Yes
o No
11. List any tests you know of that are currently covered: _________________________
12. How would you rate your organization relative to other health plans regarding your level
of management of pharmacogenetic testing?
Not at all
managed
o

Slightly managed
o

Somewhat
managed
o

Moderately
managed
o

Highly managed
o

13. Please rate your level of familiarity with preemptive pharmacogenetic testing.



Preemptive
multi-gene
pharmacogene
tic testing



Broad screening of multiple pharmacogenes
Pharmacologic effects of most medications are determined by multiple
pharmacogene products
Test results are available in the medical record as a pre-prescription
patient characteristic (independent of whether a patient is going to
receive a high-risk medicine)
Array-based preemptive testing can include a large number of relevant
pharmacogenes that cover most drugs that have a pharmacogenetic
implication for dosing

Not at all
familiar
o

Slightly
familiar
o

Somewhat
familiar
o
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Moderately
familiar
o

Very
familiar
o

14. Has preemptive pharmacogenetic testing been discussed at any of your P&T meetings in
the last two years?
o Yes
o No
o Don’t know
15. Does your organization have a formal approach to covering preemptive pharmacogenetic
testing?
o Yes
o No, but in the process of putting one together and will have one in the next
few years
o No, and no plans for the future
16. Are you aware of the clinical setting implementations of any preemptive
pharmacogenetic programs?
o Yes
o No
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Good Morning,

Thank you for participating in the first portion of the academic research on Preemptive
Pharmacogenetic Testing. I am writing to invite you to participate in Part 2 of the research.

This portion of the research includes a 30-45 minute telephone discussion with Nick Keeling to
be conducted sometime between Monday, May 23 and Friday June 3. Please contact
<<<project coordinator>>> at (XXX) XXX-XXX ext. XXX OR email <<<project
coordinator>>> at <<<email address>>> to schedule.

Please be certain to provide <<<project coordinator>>> with the telephone number we should
call you at for your interview.

As a reminder, this study has been reviewed by The University of Mississippi’s Institutional
Review Board (IRB). If you have any questions, concerns, or reports regarding your rights as a
participant of research, please contact the IRB at (662) 915-7482 or irb@olemiss.edu.

Thank you.
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APPENDIX E – SEMI-STRUCTURED INTERVIEW GUIDE
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Thank you for agreeing to participate in this study. My name is Nick Keeling and I am
conducting interviews with payer decision-makers regarding their perspectives on
pharmacogenetic testing, with an emphasis on germline, preemptive testing, and the coverage
policies associated with this technology.
I also want to inform you that I’ll be recording this interview so that I don’t waste your time
taking notes. Your name and the name of your organization will remain confidential. We expect
this interview to take approximately 45 minutes. You may withdraw from the interview at any
time. Do you have any questions for me before we begin?
Please refer to the pre-read information that was provided to you in the invitation email.

Pharmacogenetic
testing

Reactive single-gene
pharmacogenetic
testing

Preemptive multigene
pharmacogenetic
testing

Clinical
Pharmacogenetics
Implementation
Consortium (CPIC)

Broad definition: Pharmacogenetics is the study of how genes affect a person’s
response to drugs.
 Somatic Pharmacogenetics – The study of how acquired genomic variants
influence response to drug , this type of pharmacogenetics is mostly
relevant in malignancies to guide the choice of anticancer therapy (typically
a companion diagnostic)
 Germline Pharmacogenetics - The study of how inherited genomic
variants influence alterations in a drug's pharmacokinetic and
pharmacodynamics properties
 Single-gene test ordered one at a time when patient is likely to need a
pharmacogenetically high-risk drug
 Adopted into clinical practice first because of strong monogenic gene-drug
associations
 Decision based on likelihood that a high-risk drug will be prescribed for a
patient or group of patients
 Increased likelihood that the genetic test result is applied by the clinician
because the prescribing decision is linked to performance of genetic test
 Broad screening of multiple pharmacogenes
 Pharmacologic effects of most medications are determined by multiple
pharmacogene products
 Test results are available in the medical record as a pre-prescription patient
characteristic (independent of whether a patient is going to receive a highrisk medicine)
 Array-based preemptive testing can include a large number of relevant
pharmacogenes that cover most drugs that have a pharmacogenetic
implication for dosing





Assesses clinical validity (the ability of the test to differentiate between
responders and nonresponders, or to identify patients who are at risk for
adverse drug-reactions) of gene-drug pairs to determine those that are
clinically actionable
These guidelines adhere to the Institute of Medicine's Standards for
Developing Trustworthy Clinical Practice Guidelines
CPIC recommendations are in four levels: A, B, C, D
o A - Genetic information should be used to change prescribing of
affected drug
o B - Genetic information could be used to change prescribing of the
affected drug because alternative therapies/dosing are extremely
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likely to be as effective and as safe as non-genetically based dosing
C - There are published studies at varying levels of evidence, some
with mechanistic rationale, but no prescribing actions are
recommended because (a) dosing based on genetics convincingly
makes no difference or (b) alternatives are unclear, possibly less
effective, more toxic, or otherwise impractical.
o D - There are few published studies, clinical actions are unclear,
little mechanistic basis, mostly weak evidence, or substantial
conflicting data. If the genes are not widely tested for clinically,
evaluations are not needed.
 There are currently 41 gene-drug pairs that are listed level A.
 Gene-drug pairs are considered for several reasons:
o Actionable in professional society guideline
o Nominated by CPIC member or outside advocate like FDA
o PharmGKB annotation level 1A, 1B, 2A, 2B
 PharmGKB is a pharmacogenomics knowledge resource
managed by Stanford University that focuses on genotypebased summaries of the association between a drug and
the gene variant
o Mentioned in professional society guidelines but not actionable
CDS Alert trigger
CDS
CDS Alert Text (specific wording of the alert
Condition
Context,
text may differ among programs)
Relative
to
Genetic
Testing
No CYP2C19 test on Pre-test
CYP2C19 genetic status may be predictive of an
file and citalopram
adverse reaction or poor response to this
ordered
medication. A CYP2C19 genotype does not
appear to have been ordered for this patient. Use
of an alternative drug or dose may be
recommended. Please consult a clinical
pharmacist for more information.
CYP2C19 UM and
Post-test
This patient is predicted to be a CYP2C19
citalopram ordered
ultrarapid metabolizer and may be at an
increased risk of a poor response due to low
plasma concentrations of citalopram. Consider
selecting an alternative SSRI not extensively
metabolized by CYP2C19. Please consult a
clinical pharmacist for more information.
CYP2C19 EM or
Post-test
No CDS
IM and citalopram
ordered
CYP2C19 PM and
Post-test
This patient is predicted to be a CYP2C19 poor
citalopram ordered
metabolizer and may be at an increased risk of
an adverse reaction due to elevated citalopram
plasma concentrations. Consider a 50%
reduction of the recommended starting dose and
titrate to response or select alternative drug not
predominantly metabolized by CYP2C19. Please
consult a clinical pharmacist for more
information.
o

Example of Clinical
Decision Support
from preemptive
test
CYP2C19 citalopram
(https://www.pharmg
kb.org/guideline/PA1
66127638)
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Implementation of
preemptive
pharmacogenetics in
healthcare settings













Pharmacogenomics Research Network (PGRN) formed the Translational
Pharmacogenetic Program (TPP)
o Implement routine, pharmacogenetically based prescribing within
diverse health-care systems
Vanderbilt University Medical Center (VUMC), Mayo Clinic, Mount Sinai
Medical Center, St. Jude Children's Research Hospital, University of
Florida, and the University of Chicago have all implemented programs using
a preemptive pharmacogenetic approach
VUMC PREDICT program - 5 year retrospective study of 52,942 medical
home patients found that 54% of patients were exposed to at least one
medication with a known pharmacogenetic response. 383 adverse events
were hypothetically avoided.
St. Jude Children's Research Hospital - currently 7 genes coupled with
17 high-risk drugs with upwards of 55 corresponding clinical decision
support prescribing guidelines. Approximately 3,500 patients enrolled to
date
The University of Chicago - "1,200 Patients Project" - As of 2014, 812
patients enrolled and 608 genotyped. Developed a genomic prescribing
system using red (high-risk), yellow(caution), and green (favorable) lights.
At 268 clinic encounters, 86% of physicians accessed the GPS with 100%,
72%, and 20% click frequencies for the respective signals
Other preemptive pharmacogenetic implementations
o Inova Health System MediMapTM PGx Test offered to all newborns
currently and expanding to all ages soon
o Northshore University Health System (teaching afflation)
 Currently testing pharmacogenes corresponding to13
drugs

Introductory questions:
1. Please briefly describe to me your decision making role at your organization. Does your
organization have a medication technology/tech assessment committee? How often do you
meet?
2. What is your organization's approach to the movement of precision medicine? Is this
something that is discussed regularly?
3. What are your current perceptions of the market for pharmacogenetic testing?
a. How would you define value for a pharmacogenetic test?
4. How does the evaluation of a pharmacogenetic test differ from other types of health
technology? Or does it?
5. How often does your medical technology committee evaluate a new pharmacogenetic test?
6. What evidence does your medical technology committee consider when evaluating a
pharmacogenetic test?
a. What facilitators and barriers are there to covering pharmacogenetic tests?
7. What is the budget impact of this type of technology? Explain to me if your organization has
experienced any budget / financial issues with paying for pharmacogenetic testing.
a. Do you currently contract with a major laboratory for these types of testing?
(LabCorp, Quest, etc)
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Clinical Validity and Utility of Pharmacogenetic Testing
11. Were you aware of the work from CPIC prior to this interview? What impact does this have
on your assessment of the clinical validity of pharmacogenetic testing?
12. What type of trial use or data would be most helpful in the decision-making process for your
med tech committee? Is the RCT still the "gold standard"?
a. Probe: Issues with the RCT (affects outliers more and thus incremental benefit appears
small in large samples, ethical issues with knowingly giving drug to a non-responder)
b. Probe: Retrospective studies of before and after preemptive implementation?
13. How do you define clinical utility for pharmacogenetic tests?
a. Probe: Ability to prevent adverse events more quickly, prescribing the right drug the first
time.
14. In the absence of an RCT, what other types of evidence would you consider most influential
in policy development?
a. Probe: Better outcomes, change in prescribing, cost-effectiveness, society guidelines?
b. Would you consider CPIC guidelines evidence of clinical utility?
15. What impact could preemptive genetic testing have on patient outcomes?
a. Is this different than the reactive/point-of-care pharmacogenetic testing method?

Perception of Value and Cost Factors Associated with Pharmacogenetic Tests
16. Have you reviewed any pharmacoeconomic data on pharmacogenetic testing?
17. What economic impact do you see preemptive pharmacogenetic testing having on your plan?
Probe: A well-known pharmacogenetic assay that tests for 231 genes related to drug
metabolism is approximately double the cost of a single gene test.
18. Do you believe preemptive pharmacogenetic testing is a preventive technology?
a. Discuss your thoughts on the role of preemptive pharmacogenetic testing value-based
payment environment.
b. What economic drawbacks can you see from this?
19. Are you familiar with the prices for any pharmacogenetic tests that are currently available,
either multi-gene or single-gene assays?
a. Probe: Provide info that multi-gene assay is $560 vs. single-gene of $225
b. Ask if familiar: Is there a price where you would consider adopting preemptive
pharmacogenetic testing more readily? Or does price even matter (i.e. more clinical)?
Coverage and reimbursement issues for pharmacogenetic testing
20. Does your organization approach coverage policy for somatic pharmacogenetic testing
(companion diagnostics) and germline pharmacogenetic testing (pharmacokinetics)
differently? What are the factors?
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a. Cost of associated drug? Severity of the underlying disease for pharmacogenetic-guided
treatment? Potential severity of the adverse effect?
21. Discuss what the coverage and reimbursement decision-making process for a preemptive
pharmacogenetic test would look like.
a. How would the potential time gap between administering a preemptive pharmacogenetic
test and clinical utility have an impact on coverage policy?
b. Discuss your thoughts on restricting access to sub-sets of beneficiaries that might realize
positive outcomes sooner than others from pharmacogenetic testing.
c. Is determining coverage of preemptive testing more complex than reactive?
d. Is there a certain number of actionable gene-drug pairs or disease areas that need to be
covered by the test to make in reimbursable?
22. What is the average amount of time a beneficiary spends with your plan?
a. What implications might the time-gap have on policy development?
23. Are you familiar with the CMS program called "coverage with evidence development
program" to assess the clinical utility of the test in practice?
a. Has your organization ever addressed this approach or would this be considered?
24. Does the utilization of preemptive pharmacogenetics in practice (Vanderbilt, St. Jude, U of
Chicago, Inova Health, etc) have an impact on your decision to cover or not?

That is all the questions I have for you today. Would you like to add anything to our discussion
on preemptive pharmacogenetic testing or pharmacogenetic testing more generally?
If you have any further questions about the study feel free to reach to me. My email is
njkeelin@go.olemiss.edu. Thank you for your time.
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Please indicate your level of agreement or disagreement with the following statements on the
following scale.
Strongly
disagree

o

Disagree

o

Neither agree or
disagree

o

Agree

o

Strongly agree

o

1. The clinical validity of the gene-drug pairs determined by the Clinical Pharmacogenetic
Implementation Consortium (CPIC™) makes pharmacogenetic testing more actionable
for clinicians.
2. Clinical value is/will be added when clinicians have access to pharmacogenetic data in
the electronic health record (EHR) at the time of diagnosis and prescribing.
3. The influence of preemptive pharmacogenetic testing on clinician decision-making is/will
be an important consideration when evaluating coverage decision.
4. Preemptive pharmacogenetic testing will provide greater clinical value to the patient and
clinician by testing hundreds of genetic variants prior to prescribing.
5. Pharmacoeconomic data and demonstration of cost-effectiveness is/will be important in
determining coverage decisions for pharmacogenetic testing.
6. The constructing of reimbursement policies for preemptive pharmacogenetic testing may
be burdensome.
7. Clinician adoption and the endorsement of medical societies for preemptive
pharmacogenetic testing is/will be an important factor when developing coverage
policies.
8. FDA labeling of pharmacogenetic information on approved drugs will impact my
coverage decision.
9. Adoption by CMS and other third-party payers would influence my organization to
likewise develop coverage policies for preemptive pharmacogenetic testing.
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